Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.61 |
| ▸ | PNMT | P11086 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267030 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4TAAR1PNMT | |
| SCHEMBL22229845 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4TAAR1PNMT | |
| Hydrochloric Acid SCHEMBL4519421 | 0.98 | SLC6A2 (0.95) | SLC6A2SLC6A3SLC6A4TAAR1PNMT | |
| Hydrochloric Acid SCHEMBL4363928 | 0.98 | SLC6A2 (0.95) | SLC6A2SLC6A3SLC6A4TAAR1PNMT | |
| Methane SCHEMBL19285556 | 0.98 | SLC6A2 (0.95) | SLC6A2SLC6A3SLC6A4TAAR1PNMT | |
| Hydrochloric Acid SCHEMBL3279916 | 0.98 | SLC6A2 (0.95) | SLC6A2SLC6A3SLC6A4TAAR1PNMT | |
| Hydrochloric Acid SCHEMBL1168686 | 0.98 | SLC6A2 (0.95) | SLC6A2SLC6A3SLC6A4TAAR1PNMT | |
| SCHEMBL9468251 | 0.94 | SLC6A2 (0.88) | SLC6A2SLC6A3SLC6A4TAAR1PNMT | |
| SCHEMBL20714984 | 0.94 | SLC6A2 (0.88) | SLC6A2SLC6A3SLC6A4TAAR1PNMT | |
| Sulfuric Acid SCHEMBL11130866 | 0.88 | SLC6A2 (0.78) | SLC6A2SLC6A3SLC6A4TAAR1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 579 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-115379759-A | Pest control method, pest control agent composition, and pest control agent set | 日本曹达株式会社 | 2022-11-22 | — | — | CN | claimed |
| US-20150072881-A1 | Methods to Assess Treatment Outcomes in Reward Deficiency Syndrome (RDS) Behaviors Utilizing Expression Profiling | BLUM KENNETH (US) | 2015-03-12 | — | — | US | claimed |
| EP-2646578-A2 | METHODS TO ASSESS TREATMENT OUTCOMES IN REWARD DEFICIENCY SYNDROME (RDS) BEHAVIORS UTILIZING EXPRESSION PROFILING | Blum, Kenneth (US) | 2013-10-09 | — | — | EP | claimed |
| WO-2012074550-A2 | METHODS TO ASSESS TREATMENT OUTCOMES IN REWARD DEFICIENCY SYNDROME (RDS) BEHAVIORS UTILIZING EXPRESSION PROFILING | BLUM KENNETH (US) | 2012-06-07 | — | — | WO | claimed |
| US-20120142543-A1 | Methods to assess treatment outcomes in Reward Deficiency Syndrome (RDS) behaviors utilizing expression profiling | BLUM KENNETH (US) | 2012-06-07 | — | — | US | claimed |
| US-20080200376-A1 | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction | MERCK & CO., INC. | 2008-08-21 | — | — | US | claimed |
| EP-1807102-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND SEXUAL DYSFUNCTION | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006049933-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND SEXUAL DYSFUNCTION | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | claimed |
| US-4297346-A | PSYCHOACTIVE DRUGS BONDED TO NEUROPEPTIDES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1981-10-27 | — | — | US | claimed |
| US-20260132151-A1 | NOVEL N,N-DIMETHYLTRYPTAMINE (DMT) DERIVATIVES AND USES THEREOF | MIHKAL GMBH (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12612371-B2 | Sigma-1 receptor ligands and therapeutic uses thereof | UNIVERSITE DE STRASBOURG (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595269-B2 | Morpholine-like monoamine releasers | Solvonis Therapeutics Ireland Holdings Limited (IE) | 2026-04-07 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4000280-A | PHARMACEUTICAL COMPOSITIONS CONTAINING AN AMPHETAMINE DERIVATIVE FOR THE ALLEVIATION OF ANXIETY OR TREATMENT OF DEPRESSION | ASTRA LAKEMEDEL AKTIEBOLAG (SW) | 1976-12-28 | — | — | US | disclosed |
| US-3996381-A | ANTIDEPRESSANT | ASTRA LAKEMEDEL AKTIEBOLAG (SW) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612371-B2 | Sigma-1 receptor ligands and therapeutic uses thereof | SIGMAR1, OPRL1, OPRM1 | SLC6A2 361/4885SLC6A3 325/4885SLC6A4 377/4885 |
| US-20080200376-A1 | Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction | MC4R, MC5R, MC3R | SLC6A2 203/4885SLC6A3 210/4885SLC6A4 284/4885 |
| US-20260132151-A1 | NOVEL N,N-DIMETHYLTRYPTAMINE (DMT) DERIVATIVES AND USES THEREOF | HNMT, HTR6, OPRM1 | SLC6A2 33/4885SLC6A3 44/4885SLC6A4 18/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | SLC6A2 49/4885SLC6A3 44/4885SLC6A4 45/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | SLC6A2 1385/4885SLC6A3 779/4885SLC6A4 1599/4885 |
| US-12595269-B2 | Morpholine-like monoamine releasers | HTR3B, HTR3D, SLC6A3 | SLC6A2 19/4885SLC6A3 3/4885SLC6A4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.